摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4'-丙基-[1,1'-联苯]-4-胺 | 60040-12-2

中文名称
4'-丙基-[1,1'-联苯]-4-胺
中文别名
——
英文名称
4'-propyl-[1,1'-biphenyl]-4-amine
英文别名
4-(4'-propylphenyl)aniline;4-(4-Propylphenyl)aniline
4'-丙基-[1,1'-联苯]-4-胺化学式
CAS
60040-12-2
化学式
C15H17N
mdl
MFCD12824134
分子量
211.307
InChiKey
UNHOIPHYTXGJQL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 密度:
    1.024

计算性质

  • 辛醇/水分配系数(LogP):
    4
  • 重原子数:
    16
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    26
  • 氢给体数:
    1
  • 氢受体数:
    1

安全信息

  • 海关编码:
    2921499090
  • 危险性防范说明:
    P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:464c33b55e1f6bb9db2ce84ac99bf4d1
查看

反应信息

  • 作为反应物:
    描述:
    4'-丙基-[1,1'-联苯]-4-胺三乙酰氧基硼氢化钠三乙胺 作用下, 以 二氯甲烷1,2-二氯乙烷 为溶剂, 生成 tert-butyl [(2S)-1-{(4′-propylbiphenyl-4-yl)-[2-(pyridin-2-yl)cyclopropanecarbonyl]amino}-3-methylbutan-2-yl]carbamate
    参考文献:
    名称:
    Discovery of a Potent, Selective, and Brain-Penetrant Small Molecule that Activates the Orphan Receptor GPR88 and Reduces Alcohol Intake
    摘要:
    The orphan G-protein-coupled receptor GPR88 is highly expressed in the striatum. Studies using GPR88 knockout mice have suggested that the receptor is implicated in alcohol seeking and drinking behaviors. To date, the biological effects of GPR88 activation are still unknown due to the lack of a potent and selective agonist appropriate for in vivo investigation. In this study, we report the discovery of the first potent, selective, and brain-penetrant GPR88 agonist RTI-13951-33 (6). RTI-13951-33 exhibited an EC50 of 25 nM in an in vitro cAMP functional assay and had no significant off-target activity at 38 GPCRs, ion channels, and neurotransmitter transporters that were tested. RTI-13951-33 displayed enhanced aqueous solubility compared to (1R,2R)-2-PCCA (2) and had favorable pharmacokinetic properties for behavioral assessment. Finally, RTI-13951-33 significantly reduced alcohol self-administration and alcohol intake in a dose-dependent manner without effects on locomotion and sucrose self-administration in rats when administered intraperitoneally.
    DOI:
    10.1021/acs.jmedchem.8b00566
  • 作为产物:
    描述:
    4-丙基苯硼酸对碘苯胺 在 bis-triphenylphosphine-palladium(II) chloride 、 sodium carbonate 作用下, 以 异丙醇 为溶剂, 反应 2.0h, 以91%的产率得到4'-丙基-[1,1'-联苯]-4-胺
    参考文献:
    名称:
    联苯类液晶材料的制备方法
    摘要:
    本发明提供了一种联苯类液晶材料的制备方法,所述联苯类液晶材料如式I所示所述联苯类液晶材料的制备包括如下步骤:1)合成:在第一有机溶剂里,将式II的化合物式III的化合物和碱,在催化剂的作用下加热发生铃木反应:其中,R1为‑F或‑NH2,R2为具有3‑7个碳原子的烷基、具有3‑7个碳原子的不饱和烃基或具有3‑7个碳原子的烷氧基,L1,L2,L3和L4分别为H或F,m为0,1或2,X为‑Cl,‑Br或‑I,为或2)提纯:上述反应完成后,用索式提取器对步骤1)反应产物进行提纯。本发明提供的联苯类液晶材料的制备提纯方法,仪器简单,操作方便,节省时间,纯度高,损失少。
    公开号:
    CN106397288B
点击查看最新优质反应信息

文献信息

  • [EN] ELECTROACTIVE COMPOUNDS<br/>[FR] COMPOSÉS ÉLECTROACTIFS
    申请人:DU PONT
    公开号:WO2017210072A1
    公开(公告)日:2017-12-07
    There is provided a compound having Formula (I): (I). In the formula: NpHet is a naphthalene core having at least one fused 5-membered heteroaromatic ring, where the heteroaromatic ring has one heteroatom which is O, S, Se, or Te; Ar1-Ar6 are the same or different and are a hydrocarbon aryl group, a heteroaryl group, or a deuterated analog thereof; a and b are the same or different and are 0 or 1; m and n are the same or different and are 0 or 1; with the proviso that a, b, m, and n are not all 0.
    提供一种具有化学式(I)的化合物:(I)。在该式中:NpHet是至少具有一个融合的5元杂芳环的萘核,其中杂芳环具有一个杂原子,该杂原子是O、S、Se或Te;Ar1-Ar6相同或不同,是一个碳氢芳基团、一个杂芳基团或其氘代物;a和b相同或不同,为0或1;m和n相同或不同,为0或1;但要求a、b、m和n不全为0。
  • [EN] BLUE LUMINESCENT COMPOUNDS<br/>[FR] COMPOSÉS LUMINESCENTS BLEUS
    申请人:DU PONT
    公开号:WO2015061198A1
    公开(公告)日:2015-04-30
    There is provided a compound having Formula (I). In the formula: R1, R1a, R2, and R2a are the same or different and are H, D, F, CN, alkyl, fluoroalkyl, aryl, heteroaryl, silyl, deuterated alkyl, deuterated partially-fluorinated alkyl, deuterated aryl, deuterated heteroaryl, deuterated silyl, alkoxy, aryloxy, fluoroalkoxy, siloxane, siloxy, deuteroalkoxy, deuteroaryloxy, deuterofluoroalkoxy, deuterosiloxane, or deuterosiloxy, with the proviso that at least one of R1 and R1a is heteroaryl or deuterated heteroaryl; R3 , R3a, R4, R4a, R5, and R6 are the same or different at each occurrence and are D, F, CN, alkyl, fluoroalkyl, aryl, heteroaryl, silyl, deuterated alkyl, deuterated partially- fluorinated alkyl, deuterated aryl, deuterated heteroaryl, deuterated silyl, alkoxy, aryloxy, fluoroalkoxy, siloxane, siloxy, deuteroalkoxy, deuteroaryloxy, deuterofluoroalkoxy, deuterosiloxane, or deuterosiloxy, where adjacent groups selected from R3, R3a, R4, and R4a can be joined together to form a fused ring; R7 is the same or different at each occurrence and is alkyl, aryl, or deuterated analogs thereof, where two alkyl R7 groups can be joined together to make a cycloalkyi spiro ring, and where two R7 phenyl groups can be joined to form a spiro fluorene group; a and b are the same or different and are 0 or 1, with the proviso that a + b ≥ 1; x is an integer of 0- 3; y is an integer of 0-4; and z is an integer of 0-5.
    提供了具有Formula (I)的化合物。在该式中:R1、R1a、R2和R2a相同或不同,可以是H、D、F、CN、烷基、氟烷基、芳基、杂芳基、硅基、氘代烷基、氘代部分氟代烷基、氘代芳基、氘代杂芳基、氘代硅基、烷氧基、芳氧基、氟烷氧基、硅氧烷、硅氧基、氘代烷氧基、氘代芳氧基、氘代氟烷氧基、氘代硅氧烷或氘代硅氧基,但至少其中一个是杂芳基或氘代杂芳基;R3、R3a、R4、R4a、R5和R6在每次出现时相同或不同,可以是D、F、CN、烷基、氟烷基、芳基、杂芳基、硅基、氘代烷基、氘代部分氟代烷基、氘代芳基、氘代杂芳基、氘代硅基、烷氧基、芳氧基、氟烷氧基、硅氧烷、硅氧基、氘代烷氧基、氘代芳氧基、氘代氟烷氧基、氘代硅氧烷或氘代硅氧基,R3、R3a、R4和R4a中选自相邻基团可以连接在一起形成融合环;R7在每次出现时相同或不同,可以是烷基、芳基或其氘代物,其中两个烷基R7基团可以连接在一起形成环状螺环,两个R7苯基团可以连接在一起形成螺联苯基团;a和b相同或不同,可以是0或1,但要求a+b≥1;x是0-3之间的整数;y是0-4之间的整数;z是0-5之间的整数。
  • [EN] INHIBITORS OF LPXC<br/>[FR] INHIBITEURS DE LPXC
    申请人:UNIV CALIFORNIA CORP
    公开号:WO2015085238A1
    公开(公告)日:2015-06-11
    Provided herein, inter alia, are compounds and methods for treating infectious diseases. The compounds provided herein are, inter alia, useful for the treatment of bacterial infections. The compounds provided herein are, inter alia, useful inhibitors of metalloproteins, e.g. UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC).
    本文提供了用于治疗传染病的化合物和方法。本文提供的化合物可用于治疗细菌感染。本文提供的化合物是金属蛋白酶的有效抑制剂,例如UDP-3-O-(R-3-羟基肉豆蔻酰)-N-乙酰葡糖胺脱乙酰酶(LpxC)。
  • [EN] ELECTROACTIVE MATERIALS<br/>[FR] SUBSTANCES ÉLECTROACTIVES
    申请人:DU PONT
    公开号:WO2011159872A1
    公开(公告)日:2011-12-22
    There is disclosed a compound having Formula I or Formula I': In Formula I and Formula I': Ar1 and Ar2 are the same or different and are aryl groups; R1 through R5 are independently the same or different at each occurrence and are D, F, alkyl groups, aryl groups, alkoxy groups, silyl groups, or crosslinkable groups; R6 is H, D, or halogen; a through e are independently an integer from 0 to 4; f is 1 or 2; g is 0, 1 or 2; h is 1 or 2; and n is an integer greater than 0.
    披露了具有化学式I或化学式I'的化合物:在化学式I和化学式I'中:Ar1和Ar2相同或不同且为芳基基团;R1至R5在每次出现时独立相同或不同,为D、F、烷基基团、芳基基团、烷氧基团、硅基基团或交联基团;R6为H、D或卤素;a至e独立地为0至4的整数;f为1或2;g为0、1或2;h为1或2;n为大于0的整数。
  • [EN] HOLE TRANSPORT MATERIALS<br/>[FR] MATÉRIAUX DE TRANSPORT DE TROUS
    申请人:DU PONT
    公开号:WO2016010746A1
    公开(公告)日:2016-01-21
    There is disclosed a compound having Formula I. In Formula I: Ar1 and Ar3 are the same or different and are aryl groups; Ar2 and Ar4 are the same or different and are aryl groups; L is the same or different at each occurrence and can be H, D, halogen, aryl, arylamino, crosslinkable groups, deuterated aryl, deuterated arylamino, or deuterated crosslinkable groups; R1 - R4 are the same or different and can be H, D, alkyl, alkoxy, aryl, aryloxy, silyl, deuterated alkyl, deuterated alkoxy, deuterated aryl, deuterated aryloxy, or deuterated silyl; R5 - R8 are the same or different and can be D, F, alkyl, aryl, alkoxy, aryloxy, silyl, crosslinkable groups, deuterated alkyl, deuterated alkoxy, deuterated aryl, deuterated aryloxy, or deuterated silyl, where adjacent R5 - R8 groups can be joined together to form an aromatic ring; a and b are the same or different and are an integer from 0-3; c and d are the same or different at each occurrence and are an integer from 0-4; m and q are the same or different and are an integer from 1-6; and n is an integer greater than 0.
    公开了一种具有化学式I的化合物。在化学式I中:Ar1和Ar3是相同或不同的芳基基团;Ar2和Ar4是相同或不同的芳基基团;L在每次出现时相同或不同,可以是H、D、卤素、芳基、芳基氨基、交联基团、氘代芳基、氘代芳基氨基或氘代交联基团;R1-R4相同或不同,可以是H、D、烷基、烷氧基、芳基、芳氧基、硅烷基、氘代烷基、氘代烷氧基、氘代芳基、氘代芳氧基或氘代硅烷基;R5-R8相同或不同,可以是D、F、烷基、芳基、烷氧基、芳氧基、硅烷基、交联基团、氘代烷基、氘代烷氧基、氘代芳基、氘代芳氧基或氘代硅烷基,相邻的R5-R8基团可以连接在一起形成芳香环;a和b相同或不同,是0-3的整数;c和d在每次出现时相同或不同,是0-4的整数;m和q相同或不同,是1-6的整数;n是大于0的整数。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐